High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma. Pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Marec-Berard, Perrine, Segura-Ferlay, Céline, Tabone, Marie-Dominique, Pacquement, Helene, Lervat, Cyril, Gentet, Jean-Claude, Schmitt, Claudine, Gaspar, Nathalie, Brugières, Laurence
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2014
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3941142/
https://ncbi.nlm.nih.gov/pubmed/24672280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/475067
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars